Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus

Lupus

Volumn 13, Issue 12, 2004, Pages 900-905

  Ruiz Irastorza, Guillermo ^a,b   Egurbide, M V ^a   Martinez Berriotxoa, A ^a   Ugalde, J ^a   Aguirre, C ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

Anticardiolipin antibodies; Autoantibodies; Irreversible organ damage; Lupus anticoagulant; Morbidity; Mortality

Indexed keywords

AUTOANTIBODY; DNA ANTIBODY; LA ANTIGEN; PHOSPHOLIPID ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; HUMAN; INTERNATIONAL COOPERATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 10844231837     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu2030oa     Document Type: Article

References (31)

1. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001; 357: 1027-1032.
2. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
3. Gladman DD, Goldsmith CH, Urowitz MB et al. The systemic lupus erythematosus international collaborating clinics/American College of Rheumatology index for systemic lupus erythematosus international comparison. J Rheumatol 2000; 27: 373-376.
4. Manger K, Manger B, Repp R et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61: 1065-1070.
5. Rahman P, Gladman DD, Urowitz MB, Hallet D, Tam LS. Early damage as measured by the SLICC/ARC damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 93-96.
6. Ruiz-Irastorza G, Egurbide Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77-82.
7. Kavanaugh A. The utility of immunologic laboratory tests in patients with rheumatic diseases. Arthritis Rheum 2001; 44: 2221-2223.
8. Cervera R, Khamashta M. Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine (Baltimore) 1993; 72: 113-124.
9. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342-2349.
10. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
12. Thumboo J, Lee HY, Fong KY et al. Accuracy of medical record scoring of the SLICC/ACR damage index for systemic lupus erythematosus. Lupus 2000; 9: 358-362.
13. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
14. Cervera R, Piette J Ch, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-1027.
15. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-1190.
16. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-1311.
17. Altman DG, ed. Practical statistics for medical research. London: Chapman & Hall, 1991.
18. Amigo M-C, Khamashta MA. Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am 2000; 26: 331-348.
19. Zonana-Nacach A, Camargo-Coronel A, Yanez P et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 1998; 7: 119-123.
20. Mok CC, Lee KW, Ho CTK, Lau CS, Wong RWS. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology 2000; 39: 399-406.
21. Alarcón GS, Roseman JM, McGwin G Jr. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology 2003; 42: 1-4.
22. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248-254.
23. Jouhikainen T, Stephansson E, Leirisalo-Repo M. Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheumatol 1993: 32: 568-573.
24. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcon GS. Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival. J Rheumatol 1993; 20: 1684-1693.
25. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in chilhood-onset systemic lupus erythematosus. Arthritis Rheum 2002; 46: 436-444.
26. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 2003; 42: 276-279.
27. Galli M, Luciani D, Bertolini G. Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
28. Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62: 556-560.
29. Arbuckle MR, McClain MT, Rubertone MV et al Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
30. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arch Intern Med 2000; 160: 2042-2048.
31. Khamashta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmunity 2000; 15: 249-253.